trifluoperazine has been researched along with Breast Neoplasms in 12 studies
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We conducted a clinical trial to determine whether the P-gp inhibitor, trifluoperazine, could sensitize patients with refractory breast cancer to vinblastine chemotherapy." | 9.08 | Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer. ( Buzaid, AC; Carter, D; Durivage, HJ; Flynn, SD; Hait, WN; Murren, JR; Reiss, M, 1996) |
| "The effects of anticalmodulin agents, namely trifluoperazine (TFP) and two naphthalene sulfonamide derivatives (W-7 and W-13), were tested on the growth of a human breast cancer cell line (MDA-MB-231) using a soft agar clonogenic assay." | 7.66 | Inhibition of human breast cancer colony formation by anticalmodulin agents: trifluoperazine, W-7, and W-13. ( Hickie, RA; Klaassen, DJ; Wei, JW, 1983) |
| "Twenty patients with metastatic breast cancer were treated every 3 weeks with TFP 5 mg by mouth every 6 hours on days 0-5 and doxorubicin 60 mg/m2/96 hr on days 1-4 by continuous intravenous infusion." | 6.67 | Phase II trial of doxorubicin and trifluoperazine in metastatic breast cancer. ( Bauer, L; Budd, GT; Bukowski, RM; Ganapathi, R; Lichtin, A; Van Kirk, P, 1993) |
| " We conducted a clinical trial to determine whether the P-gp inhibitor, trifluoperazine, could sensitize patients with refractory breast cancer to vinblastine chemotherapy." | 5.08 | Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer. ( Buzaid, AC; Carter, D; Durivage, HJ; Flynn, SD; Hait, WN; Murren, JR; Reiss, M, 1996) |
| " Treatment of human MCF-7 breast cancer cells with chemosensitizers (CS), such as verapamil, trifluoperazine or BSO, for 72 hr resulted in an enhanced sensitization of cells to Adriamycin, trifluoperazine being the most potent compound in the reversion of chemoresistance." | 3.69 | Comparative study of intracellular calcium and adenosine 3',5'-cyclic monophosphate levels in human breast carcinoma cells sensitive or resistant to Adriamycin: contribution to reversion of chemoresistance. ( Hénichart, JP; Hornez, L; Mestdagh, N; Vandewalle, B, 1994) |
| "The effects of anticalmodulin agents, namely trifluoperazine (TFP) and two naphthalene sulfonamide derivatives (W-7 and W-13), were tested on the growth of a human breast cancer cell line (MDA-MB-231) using a soft agar clonogenic assay." | 3.66 | Inhibition of human breast cancer colony formation by anticalmodulin agents: trifluoperazine, W-7, and W-13. ( Hickie, RA; Klaassen, DJ; Wei, JW, 1983) |
| "Twenty patients with metastatic breast cancer were treated every 3 weeks with TFP 5 mg by mouth every 6 hours on days 0-5 and doxorubicin 60 mg/m2/96 hr on days 1-4 by continuous intravenous infusion." | 2.67 | Phase II trial of doxorubicin and trifluoperazine in metastatic breast cancer. ( Bauer, L; Budd, GT; Bukowski, RM; Ganapathi, R; Lichtin, A; Van Kirk, P, 1993) |
| "While bone is a frequent target of breast cancer-associated metastasis, little is known about the effects of tumor-bone interactions on the efficacy of tumor-suppressing agents." | 1.48 | Osteocyte-Driven Downregulation of Snail Restrains Effects of Drd2 Inhibitors on Mammary Tumor Cells. ( Chen, A; Fan, Y; Jalali, A; Li, BY; Liu, S; Minami, K; Nakshatri, H; Ogawa, K; Yokota, H, 2018) |
| " The effects of ospemifene (OSP) on the immune response to a peptide cancer vaccine (PV) were evaluated after chronic [control (n = 22); OSP 50 mg/kg (n = 16); PV (n = 6); OSP+PV (n = 11)], intermittent [control (n = 10); OSP 10 and 50 mg/kg (n = 11); PV (n = 11); combination treatment (n = 11 each dose)] and pretreatment [control; OSP 100 mg/kg; PV 100 μg; combination treatment (n = 8 all groups)] ospemifene oral dosing schedules in a total of 317 mixed-sex tumor-bearing and nontumor-bearing mice." | 1.46 | Repurposing ospemifene for potentiating an antigen-specific immune response. ( DeGregorio, MW; Kao, CJ; Lin, YC; Phong, B; Vang, DP; Wurz, GT, 2017) |
| "Triple-negative breast cancer (TNBC) is the most lethal form of breast cancer." | 1.43 | Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo. ( Berek, JS; Chung, YM; Hu, MC; Ma, J; Park, SH; Yang, Q, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (25.00) | 18.7374 |
| 1990's | 4 (33.33) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, S | 1 |
| Fan, Y | 1 |
| Chen, A | 1 |
| Jalali, A | 1 |
| Minami, K | 1 |
| Ogawa, K | 1 |
| Nakshatri, H | 1 |
| Li, BY | 1 |
| Yokota, H | 1 |
| Park, SH | 1 |
| Chung, YM | 1 |
| Ma, J | 1 |
| Yang, Q | 1 |
| Berek, JS | 1 |
| Hu, MC | 1 |
| Kao, CJ | 1 |
| Wurz, GT | 1 |
| Lin, YC | 1 |
| Vang, DP | 1 |
| Phong, B | 1 |
| DeGregorio, MW | 1 |
| Fancy, RM | 1 |
| Kim, H | 1 |
| Zhou, T | 1 |
| Zinn, KR | 1 |
| Buchsbaum, DJ | 1 |
| Song, Y | 1 |
| Anders, L | 1 |
| Mertins, P | 1 |
| Lammich, S | 1 |
| Murgia, M | 1 |
| Hartmann, D | 1 |
| Saftig, P | 1 |
| Haass, C | 1 |
| Ullrich, A | 1 |
| Dudley, B | 1 |
| Hickie, RA | 2 |
| Wei, JW | 2 |
| Blyth, LM | 1 |
| Wong, DY | 1 |
| Klaassen, DJ | 2 |
| Frankfurt, OS | 1 |
| Sugarbaker, EV | 1 |
| Robb, JA | 1 |
| Villa, L | 1 |
| Mestdagh, N | 1 |
| Vandewalle, B | 1 |
| Hornez, L | 1 |
| Hénichart, JP | 1 |
| Budd, GT | 1 |
| Bukowski, RM | 1 |
| Lichtin, A | 1 |
| Bauer, L | 1 |
| Van Kirk, P | 1 |
| Ganapathi, R | 1 |
| Murren, JR | 1 |
| Durivage, HJ | 1 |
| Buzaid, AC | 1 |
| Reiss, M | 1 |
| Flynn, SD | 1 |
| Carter, D | 1 |
| Hait, WN | 1 |
1 review available for trifluoperazine and Breast Neoplasms
| Article | Year |
|---|---|
Cations and calmodulin in normal and neoplastic cell growth regulation.
Topics: Breast Neoplasms; Calcium; Calmodulin; Cell Division; Cell Line; Female; Humans; Magnesium; Neoplasm | 1983 |
2 trials available for trifluoperazine and Breast Neoplasms
| Article | Year |
|---|---|
Phase II trial of doxorubicin and trifluoperazine in metastatic breast cancer.
Topics: Adult; Breast Neoplasms; Doxorubicin; Drug Resistance; Drug Therapy, Combination; Female; Humans; Mi | 1993 |
Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Membe | 1996 |
9 other studies available for trifluoperazine and Breast Neoplasms
| Article | Year |
|---|---|
Osteocyte-Driven Downregulation of Snail Restrains Effects of Drd2 Inhibitors on Mammary Tumor Cells.
Topics: Animals; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast; Breast Neoplasms; Cell Culture Tec | 2018 |
Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo.
Topics: Animals; Apoptosis; Bepridil; Breast Neoplasms; Cell Nucleus; Dopamine; Female; Forkhead Box Protein | 2016 |
Repurposing ospemifene for potentiating an antigen-specific immune response.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Calmodulin; Cancer Vaccin | 2017 |
Calmodulin Binding to Death Receptor 5-mediated Death-Inducing Signaling Complex in Breast Cancer Cells.
Topics: Breast Neoplasms; Calmodulin; Cell Line, Tumor; Cell Survival; Death Domain Receptor Signaling Adapt | 2017 |
Furin-, ADAM 10-, and gamma-secretase-mediated cleavage of a receptor tyrosine phosphatase and regulation of beta-catenin's transcriptional activity.
Topics: ADAM Proteins; ADAM10 Protein; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopept | 2006 |
Treatment of the artificial menopause.
Topics: Barbiturates; Breast Neoplasms; Carcinoma; Castration; Female; Humans; Mastectomy; Menopause; Middle | 1967 |
Inhibition of human breast cancer colony formation by anticalmodulin agents: trifluoperazine, W-7, and W-13.
Topics: Breast Neoplasms; Calmodulin; Cell Division; Cell Line; Female; Humans; Sulfonamides; Trifluoperazin | 1983 |
Synergistic induction of apoptosis in breast cancer cells by tamoxifen and calmodulin inhibitors.
Topics: Apoptosis; Breast Neoplasms; Calmodulin; Drug Synergism; Estrogen Antagonists; Female; Humans; Tamox | 1995 |
Comparative study of intracellular calcium and adenosine 3',5'-cyclic monophosphate levels in human breast carcinoma cells sensitive or resistant to Adriamycin: contribution to reversion of chemoresistance.
Topics: Binding Sites; Breast Neoplasms; Calcium; Cell Line; Cyclic AMP; Doxorubicin; Drug Resistance; Gluta | 1994 |